Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche bearbeiten
Filter bei nächster Suche beibehalten
format_facet:"Elektronische Ressource"
topic_facet:"B72HH48FLU"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=format_facet%3A%22Elektronische+Ressource%22&filter%5B%5D=topic_facet%3A%22B72HH48FLU%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%221365-2036%22&type0%5B%5D=ISN&op0%5B%5D=OR
/vufind/Search/Results?filter%5B%5D=format_facet%3A%22Elektronische+Ressource%22&filter%5B%5D=topic_facet%3A%22B72HH48FLU%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%221365-2036%22&type0%5B%5D=ISN&op0%5B%5D=OR
Search /vufind/Search2/Results?filter%5B%5D=format_facet%3A%22Elektronische+Ressource%22&filter%5B%5D=topic_facet%3A%22B72HH48FLU%22&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%221365-2036%22&type0%5B%5D=ISN&op0%5B%5D=OR
PubPharm (302)
1
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
enthalten in:
Alimentary pharmacology & therapeutics
| 2024
von
García, M.
|
Riestra, S.
|
Amiot, A.
| +24
Wird geladen...
2
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses : The REMSWITCH-LT study
enthalten in:
Alimentary pharmacology & therapeutics
| 2024
von
Buisson, A.
|
Nachury, M.
|
Bazoge, M.
| +6
Wird geladen...
3
Letter : Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug. Authors' reply
enthalten in:
Alimentary pharmacology & therapeutics
| 2024
von
Bokemeyer, B.
|
Plachta-Danielzik, S.
Wird geladen...
4
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease : The ADA-SWITCH study
enthalten in:
Alimentary pharmacology & therapeutics
| 2023
von
Casanova, M.
|
Nantes, .
|
Varela, P.
| +39
Wird geladen...
5
Editorial : safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis-authors' reply
enthalten in:
Alimentary pharmacology & therapeutics
| 2023
von
Dahl, E.
|
Abed, O.
|
Kjeldsen, J.
| +6
CommentOn: Aliment Pharmacol Ther. 2022 Nov;56(9):1370-1382. - PMID 36123319
Wird geladen...
6
Editorial : safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor-induced colitis
enthalten in:
Alimentary pharmacology & therapeutics
| 2023
von
Hanauer, S.
|
Wang, Y.
|
Shatila, M.
CommentOn: Aliment Pharmacol Ther. 2022 Nov;56(9):1370-1382. - PMID 36123319
Wird geladen...
7
Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis
enthalten in:
Alimentary pharmacology & therapeutics
| 2022
von
Dahl, E.
|
Abed, O.
|
Kjeldsen, J.
| +6
CommentIn: Aliment Pharmacol Ther. 2023 Jan;57(1):152-153. - PMID 36468203
Wird geladen...
8
The inexorable increase of biologic exposure in paediatric inflammatory bowel disease : a Scottish, population-based, longitudinal study
enthalten in:
Alimentary pharmacology & therapeutics
| 2022
von
Burgess, C.
|
Jackson, R.
|
Chalmers, I.
| +5
CommentIn: Aliment Pharmacol Ther. 2022 Dec;56(11-12):1619-1620. - PMID 36352749
Wird geladen...
9
Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease : results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study
enthalten in:
Alimentary pharmacology & therapeutics
| 2022
von
Chanchlani, N.
|
Lin, S.
|
Auth, M.
| +99
CommentIn: Aliment Pharmacol Ther. 2022 Oct;56(8):1294-1295. - PMID 36168263
Wird geladen...
10
Understanding anti-TNF treatment failure : does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
enthalten in:
Alimentary pharmacology & therapeutics
| 2022
von
Lin, S.
|
Chanchlani, N.
|
Carbery, I.
| +9
CommentIn: Aliment Pharmacol Ther. 2022 Sep;56(5):903-904. - PMID 35934852
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[31]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Medienart: E-Ressourcen
Filter aufheben
Thema: B72HH48FLU
Medienart
302
Aufsätze
302
E-Artikel
E-Ressourcen
Zeitschriftentitel
302
Alimentary pharmacology & therapeutics
Thema
B72HH48FLU
302
Infliximab
194
Journal Article
161
Antibodies, Monoclonal
121
Adalimumab
121
FYS6T7F842
109
Tumor Necrosis Factor-alpha
106
Comment
101
Gastrointestinal Agents
98
Research Support, Non-U.S. Gov't
71
Antibodies, Monoclonal, Humanized
57
Letter
52
Anti-Inflammatory Agents
51
Editorial
39
Review
30
Multicenter Study
27
Immunosuppressive Agents
24
Biosimilar Pharmaceuticals
24
Immunologic Factors
24
Tumor Necrosis Factor Inhibitors
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
74
2020-
199
2010-2019
29
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
302
Englisch
Haven't found what you're looking for?
Wird geladen...